For TGF-β inhibition only two clinical drugs are available so far, one is the antisense oligonucleotides AP-12009 which act directly against the mRNA of TGF-β [301] and the TGFB receptor antagonists like galunisertib, which are both used against carcinomas [302]. The gene discussed is TGFB1; the disease is carcinoma.